Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
27.91
-0.26 (-0.92%)
At close: Mar 5, 2026, 4:00 PM EST
27.91
0.00 (0.00%)
After-hours: Mar 5, 2026, 4:10 PM EST
Castle Biosciences Stock Forecast
Stock Price Forecast
The 6 analysts that cover Castle Biosciences stock have a consensus rating of "Strong Buy" and an average price target of $47.17, which forecasts a 69.01% increase in the stock price over the next year. The lowest target is $40 and the highest is $52.
Price Target: $47.17 (+69.01%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Castle Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 4 | 4 | 4 |
| Buy | 4 | 4 | 3 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Baird | Baird | Buy Maintains $41 → $44 | Buy | Maintains | $41 → $44 | +57.65% | Feb 27, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $43 → $47 | Strong Buy | Maintains | $43 → $47 | +68.40% | Jan 26, 2026 |
| Lake Street | Lake Street | Strong Buy Maintains $35 → $52 | Strong Buy | Maintains | $35 → $52 | +86.31% | Jan 12, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $30 → $43 | Strong Buy | Maintains | $30 → $43 | +54.07% | Jan 5, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $37 → $50 | Strong Buy | Maintains | $37 → $50 | +79.15% | Dec 22, 2025 |
Financial Forecast
Revenue This Year
351.46M
from 344.23M
Increased by 2.10%
Revenue Next Year
395.86M
from 351.46M
Increased by 12.63%
EPS This Year
-1.19
from -0.83
EPS Next Year
-0.59
from -1.19
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 365.4M | 410.0M | |||
| Avg | 351.5M | 395.9M | |||
| Low | 330.8M | 376.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 6.1% | 16.7% | |||
| Avg | 2.1% | 12.6% | |||
| Low | -3.9% | 7.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.83 | -0.19 | |||
| Avg | -1.19 | -0.59 | |||
| Low | -1.40 | -0.83 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.